lapatinib has been researched along with dronabinol in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (dronabinol) | Trials (dronabinol) | Recent Studies (post-2010) (dronabinol) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 8,307 | 785 | 3,094 |
| Protein | Taxonomy | lapatinib (IC50) | dronabinol (IC50) |
|---|---|---|---|
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.218 | |
| Cannabinoid receptor 1 | Homo sapiens (human) | 0.0028 | |
| Cannabinoid receptor 2 | Homo sapiens (human) | 0.0095 | |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | 0.218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and dronabinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |